PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO

PharmaCyte Biotech, Inc.

One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.
One-time grant to Carlos Trujillo (CFO): $50,000 cash and options to purchase 85,000 shares at $2.18/share.
Options vest 50% on grant date (Nov 20, 2023) and 50% on one-year anniversary.
Grants made under the PharmaCyte Biotech 2022 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.